Ziel/Aim: In VISION, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus standard of care (SoC) significantly improved overall survival and radiographic progression-free survival in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer. In the VISION dosimetry sub-study, 177Lu-PSMA-617 had a good safety profile with low radiotoxicity. Here, we present the tumor dosimetry for 177Lu-PSMA-617 across cycles 1-6.
E. Kahkonen合作论文数1A Takano合作论文数1H Sipila合作论文数1K Lehtio合作论文数1S. Borkowski合作论文数1R. Valencia合作论文数1P. Luoto合作论文数1A. Hoffmann合作论文数1
Sami Suilamo合作论文数1
Andrea Varrone合作论文数Division of Imaging Core Facilities, Department of Clinical Neuroscience, Karolinska Institutet;Centre for Psychiatry Research at CNS, Department of Clinical Neuroscience, Karolinska Institutet1
Anne Roivainen合作论文数Turku PET Centre, University of Turku and Turku University Hospital1
Andrea Thiele合作论文数1Richard Odh合作论文数1
Christer Halldin合作论文数PET Centre, Karolinska Institutet1Juha T. Rantala合作论文数1
Torsten Zimmermann合作论文数RWTH Aachen University1N Sjoholm合作论文数1
Per Karlsson合作论文数Department of Psychiatry and Psychology, Karolinska Hospital1Heikki Minn合作论文数Department of Clinical Medicine, Faculty of Medicine, University of Turku1Tuula Tolvanen合作论文数1
